BUSINESS

Moderna Stock Soars 90% After Phase 3 Cancer Vaccine Trial Success

PUBLISHED Aug 19, 2026, 7:36 PM ET

Read, Watch or Listen

Media Bias Meter

Sources: 31

Center 94%

Right 6%

Sources: 31

Moderna and Merck announced that their personalized mRNA cancer vaccine achieved its primary goal in a late-stage clinical trial. The study evaluated patients with high-risk melanoma who underwent complete surgical removal of their tumors. Administered alongside Merck immunotherapy drug Keytruda, the experimental vaccine significantly prolonged recurrence-free survival compared with Keytruda alone. The trial enrolled over one thousand participants across multiple global clinical trial sites. Executives from both companies stated that safety profiles remained consistent with earlier evaluations, showing no unexpected adverse events. Following the public disclosure, Moderna stock surge dramatically during premarket trading sessions, reflecting massive investor optimism. Merck shares also posted notable gains. Both pharmaceutical organizations plan to present comprehensive datasets at an upcoming international medical meeting. Regulatory submissions will follow shortly to pursue potential accelerated approval pathways with federal health agencies. The breakthrough represents a significant milestone for personalized mRNA therapeutics in oncology research worldwide today right now.

By Lauren Mitchell | JQJO News

Timeline of Events

On October 28, 2024: Companies initiated phase three trials targeting non-small cell lung cancer.
On January 20, 2026: Researchers released promising five-year follow-up data for skin cancer treatment.
On May 29, 2026: Detailed clinical results appeared at the annual medical oncology conference.
On August 19, 2026: Moderna and Merck announced successful phase three melanoma trial results.
On August 19, 2026: Moderna stock surged significantly during morning premarket trading sessions today.
On August 19, 2026: Merck shares climbed higher following positive late-stage clinical trial disclosures.
On August 20, 2026: Global financial markets reacted strongly to groundbreaking biotech sector developments.
In late 2026: Executives will submit comprehensive trial data packages to federal regulators.
In early 2027: Regulatory agencies may grant accelerated approval for the combination therapy.
By 2030: Personalized mRNA treatments could reshape standard oncology care practices globally.

News Intelligence

Immediate US impact: Biotech stocks surged while healthcare sector investor confidence rose sharply.
Possible long-term US impact: Personalized mRNA treatments will revolutionize oncology care across the nation.
Most affected groups: Cancer patients, biotech investors, pharmaceutical companies, and healthcare stock traders.
What Readers Should Prioritise: Monitor official regulatory announcements and upcoming medical conference presentation schedules.

Media Bias

Articles Published:: 31
Right Leaning:: 2
Left Leaning:: 0
Neutral:: 29

Explain Framing

Left: Emphasizes public health benefits and future accessibility for cancer patients. Center: Focuses strictly on clinical trial data, stock movements, and regulatory timelines. Right: Highlights corporate market gains, capitalist innovation, and biotech investment opportunities.